Use access key #2 to skip to page content.

ETFinnovators (< 20)

January 2009



Momenta Pharma: A Pure Play on Bio-Generics

January 03, 2009 – Comments (0) | RELATED TICKERS: MNTA , NVS , TEVA

Momenta Pharma (MNTA) represents a pure play investment for the future of bio-generics, with two ANDAs filed at the FDA in partnership with the Sandoz division of Novartis (NVS) for multi-billion dollar biological agents Lovenox ($3.8B in sales for 2007) (blood thinner) – Sanofi-Aventis (SNY) and Copaxone ($1.7B in sales for 2007) (multiple sclerosis) – Teva Pharma (TEVA). However, it is important to note that the ANDAs for Lovenox and Copaxone can be approved through existing pathways at the FDA and do not require the passage of legislation to make it on the market.   [more]

Featured Broker Partners